Shanghai RAAS Blood Products (002252) Q4 2024 earnings summary

Executive summary

• Revenue reached RMB 8.18 billion in 2024, up 2.67% year-over-year; net profit attributable to shareholders was RMB 2.19 billion, up 23.25% year-over-year.

• Gross margin for blood products remained robust, with overall gross margin at 40.65%.

• Cash flow from operations was negative RMB 482 million, mainly due to increased payments for imported products and early payments for supplier discounts.

• The company completed a major change in control, with Haier Group (via Haiyingkang) becoming the controlling shareholder and actual controller in July 2024.

• Proposed cash dividend of RMB 0.33 per 10 shares, with total cash dividends for the year at RMB 218.54 million.

Financial highlights

• Operating income: RMB 8.18 billion, up 2.67% year-over-year.

• Net profit attributable to shareholders: RMB 2.19 billion, up 23.25% year-over-year.

• Basic and diluted EPS: RMB 0.33, up 22.22% year-over-year.

• Total assets at year-end: RMB 33.63 billion, up 5.33% from previous year.

• Net assets attributable to shareholders: RMB 31.93 billion, up 7.74% from previous year.

Outlook and guidance

• Focus on expanding plasma collection through both organic growth and M&A, with 44 plasma stations and plans to add more via acquisition.

• Continued investment in R&D, with emphasis on innovative blood products and new indications.

• Strategic integration into Haier's healthcare ecosystem, aiming for digital transformation and enhanced operational efficiency.

• Plans to further optimize marketing, compliance, and quality management systems.

• Guidance for continued stable growth in blood product demand and market share expansion.